Cannabinoid Augmentation of Fear Response in Humans

Yale University

Status and phase: Completed; Early Phase 1

Conditions: Fear Conditioning

Treatments: Drug: PF-04457845; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01665573

120303009906

Details and patient eligibility

About

The purpose of this double blind, randomized, controlled, proof-of-concept study is to test the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On three days over not more than two weeks, subjects will be trained to associate cues with two different stimuli, then this association will be extinguished. Cannabinoid receptor stimulation will be accomplished indirectly by harnessing the brain's capacity to endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845. Some details of this study have not been disclosed to preserve the study design.

Enrollment: 31 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Between the ages of 18 and 65
• Male and female
• No major medical problems

Exclusion criteria

• Hearing problems
• Psychiatric or mental problems

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

31 participants in 2 patient groups, including a placebo group

PF-04457845

Active Comparator group

Description:

Acquisition of conditioning Administration of drug Extinction of conditioning

Treatment:

Drug: Placebo

Drug: PF-04457845

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo

Drug: PF-04457845